Juniper Pharma Services to reformulate Pharmaust candidate for Phase II trials
![](/46/pdcnewsitem/03/89/35/Nikin%20P2.jpg)
Pharmaust deal: Dr Nikin Patel, president at Juniper Pharma Services
The CDMO will also manufacture 20,000 capsules of the reformulated monepantel solution for the Australian company
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals has been selected by PharmAust Limited to reformulate monepantel (MPL) for its Phase II studies currently in planning and preparation.
The contract development and manufacturing organisation (CDMO) will also manufacture 20,000 capsules of the reformulated MPL solution for the Australian company under GMP, ensuring that the Phase II clinical data are admissible to regulators as part of any subsequent submissions.
The primary need to reformulate MPL stems from the particularly unpleasant taste of the current MPL formulation, as used at the Royal Adelaide Hospital during the Phase I study. Despite showing significant activity of MPL on tumour markers such as p70S6K and p-4E-BP1, compliance by patients in taking the drug for 28 days was poor due to nausea associated with its exceptionally poor palatability.
Dr Roger Aston, chairman at PharmAust, said: “We expect the reformulation process to take about 12 to 14 weeks, which gives us time to prepare clinical trial submissions to regulatory bodies based on the capsule format.
“We have shown that oral MPL is effectively absorbed in humans and canines yielding blood levels of the drug which have shown both safety and activity against key tumour markers.”
With an established track record of helping pharmaceutical companies develop and produce oral and topical drug products for clinical trials, Juniper Pharma Services is able to optimise formulation performance through its science-led approach to projects.
Dr Nikin Patel, president at Juniper Pharma Services, said: “We are very pleased to have secured this project with PharmAust as it further demonstrates our specific expertise in assisting companies from across the globe in reformulating and manufacturing products such as capsules for clinical trials.
“As our reputation in the market for supporting drug developers with both simple and complex formulation challenges continues to grow, we are seeing more companies approach us at an earlier stage to transform their promising concepts into finished dosage forms to deliver the best possible chance of clinical success.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance